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INTRODUCTION 
 
    Acute  viral  infections  of   the respiratory  tract  especially the  lower  
respiratory  tract    are  well known  cause of  airway  diseases  in  later  life.  
They  have  effects  on  bothin  normal   and  in  diseased  airways. 
    Almost   all  known  viral  respiratory  infections  tends  to produce  
deletrious  effects  on  the  pulmonary  functions  especially  obstructive  type  
of  airway  diseases due to  airway hyper responsiveness. 
  Certain  viruses  seem  to  have  a  particular  propensity  to cause  wheezing,  
RSV  being  most  common,  followed  by   the  parainfiuenza  viruses  and  
coronaviruses. Other  viruses  like   influenza  and rhinovirus  also  produce  the  
same  effects in  normal  lung  and  also  they  are  responsible  for the acute 
exacerbations  of   wheeze in  patients  with  airway diseases  like  bronchial  
asthma and  chronic obstructive  airway  disease. 
Even  “uncomplicated”  viral  respiratory  infection  in  adults,  ie, 
infections  with  clinical  manifestations  limited  to  the  upper  respiratory  
tract,  and  normal  chest  roentgenograms, is  commonly  associated  with  
prolonged  physiologic abnormalities,  suggestive  of  lower  respiratory  tract 
involvement. 
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     H1N1  flu infection  produced  a  significant  morbidity  and mortality  
during  the  acute  stage  of   infection during  the  year   2009  and  continued  
to 2010.  Being  a  viral  respiratory   infection  it  can  also  produce  some 
detrimental  effect  on pulmonary  function  as  like its  fellow  viruses. 
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                     OBJECTIVES OF THE STUDY 
 
1.    To  assess  the  clinical  status  of  the  patients  who  were  
 
previously  treated  for  H1N1 influenza. 
 
 
2.    To  determine  the  pulmonary  function  of  those  patients 
 
by  spirometry. 
 
 
3.    To  determine   the    relationship   between   the    severity   
 
of   the  lung  involvement  during  the  acute  infection  and 
 
the  extent  of  residual  effect  on  the  lung  fuction. 
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                            REVIEW  OF  LITERATURE  
 
  Viral  respiratory  tract  infections   may  well  be  the  most  common  ofall  
mankind’s  illnesses.  It   includes  both  upper  and  lower   respiratory tract  
infections.      Defined   etiologic    agents       include  rhinovirus,    coronavirus,    
and    parainfluenza    virus,      but      in   approximately    75   percent    of   the  
cases,    no  etiologic  agent  can   be  identified[1].      In   addition   to   the   
classic  signs  of  coryza  and   pharyngitis,   these   illnesses   are   often   
associated  with  cough  and  decreased  exercise  tolerance  more  suggestive   
of   lower  respiratory  tract   involvement.   A  number   of    physiologic   
studies    have   demonstrated  alterations  in  pulmonary function. 
    Picken   et  al [2]  documented  abnormal   frequency  dependent  dynamic  
compliance   suggestive  of  peripheral  airway   abnormalities     following 
hinovirus   infections.   In some instances,   these  abnormalities  developed  
four  to  eight  weeks   after  the  acute  onset  of   illness  and   did  not   return  
to  normal  for   an   additional  six  weeks .Cate  et  al[3] demonstrated 
diminished   steady  state  diffusing  capacity   measurements  in  subjects   with  
rhinovirus  infection,   felt  to  be   caused  by  transient  bronchiolitis. 
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           Fridy   and  coworkers[4]   found  abnormal  closing  volumes  and   
diminished  density   dependent  expiratory  flow  rates  in  smokers  with  
predominantly  rhinovirus  disease   studied   prospectively.   In  a   recent  
prospective   study   of   young   children   2.5  to  11  years  of   age,  
uncomplicated   upper  respiratory  tract  infections   were   uniformly 
associated  with  diminished  forced expiratory  flow  rates.[5]  This  study is  of  
particular  importance  since  other complicating  risk  factors  such  as  smoking  
and  long-term  air  pollution  exposure  would  be  obviated. 
More recent attention has focused on the pathophysiology of influenza virus 
infections. It has long been appreciated that individuals with underlyingchronic 
obstructive pulmonary disease are susceptible to serious, life-
threateningpulmonary complications of influenza infection.[6] Moreover, these 
casesrepresent only a small minority of the estimated 20 percent to 50 percent 
of the population at risk who  are infected during a pandemic. Previous studies 
have suggested that pulmonary  function abnormalities frequently follow 
influenza infection, even in the absence of pneumonia.[7]  Forseveral sequential 
years, we have studied airway  mechanics in groups ofotherwise healthy young 
adults with nonpneumonic naturally acquired influenzaA (H3N2) infection. 
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The  findings in these studies suggests the presence of uneven airway 
time  constants, and we theorized that a generalized  increase in flow resistance 
in  peripheral airspaces could result in the degree of frequency dependence  of 
resistance. As was noted with other viral infections, these mechanical  
abnormalities persisted  beyond the period of symptomatic illness. 
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PATHOPHYSIOLOGY OF VIRUS-LUNG INTERACTION 
 
Bronchial  Inflammation  and  Airway  Hyper  responsiveness 
              The  interactions  between  virus  and  host  are  very  complicated. 
 Although  the  relationship  between  respiratory  viral  infections  and  the  
onset  of  asthma  has  not  been  entirely  defined,  a  link  between  
exacerbations  of  bronchial  inflammation  and  enhancement  of  allergic  
airway  responses  is  much  more  clear.  Acute  infection  can  intensify  
airway  narrowing  and   airway  hyperresponsiveness  (AHR).  Viral-induced  
alterations  of  epithelial  cell  structure  and  function,  increased  inflammatory  
cell  accumulation  in      the  tissue  and  around  airways ,  edema  of  airway  
walls,  and  exposure  of         airway  nerve  endings  in  sites  of  epithelial  cell  
sloughing  contribute  to  altered  airway  function.[8]  These  alterations  in  
airway  function  may  contribute to  asthma  exacerbation. 
Viral-Induced  Effectors  of  the  Inflammatory  Response 
Adhesion  Molecules 
       The  complexity  of  the  effects  of  respiratory  infection  on  airway  
function  are   underscored  by   the   many   cell-mediated   immune   responses   
to  viruses  (Figure).  Increased  expression  of  a  number  of  important  
adhesion  molecules can  be  detected  in  response   to   infection.    These  
proteins  regulate inflammatory  cell  migration,  enhancing  airway  
 
 
8
inflammatory  responses.  One example  is  intercellular  adhesion  molecule 1 
(ICAM-1),  a  molecule  in  which expression  is  increased  during   and   
following  viral  infection.  ICAM-1   is expressed  on  a  wide  variety  of  cells,  
including  epithelial  cells,  endothelial cells,  fibroblasts,  lymphocytes,  and  
monocytes.  Expression  of  ICAM-1  is  increased  by  the  pro-inflammatory  
mediators  (cytokines)  interferon-gamma, interleukin  (IL)-1,  and  tumor  
necrosis  factor  (TNF). 
           ICAM-1  is  the  major  human  rhinovirus  receptor.  Upregulation   of 
ICAM-1  has  been  detected  following  experimental   rhinovirus    infection. 
Binding  of  the  virus  to  ICAM-1  on  different  cell  types  triggers  the  
release of  a  number  of  cytokines  and  further  increases  in  ICAM-1  
expression  on adjacent  cells,  thereby  enhancing  adhesion  and  spread  of  the  
virus.  With increased  expression  of  ICAM-1,  eosinophil  and  neutrophil   
migration, adhesion  and  attraction  are  augmented;  this  leads  to  enhanced  
inflammation, which  increases  AHR.  Support  for  this  pathway  in  the  
pathogenesis  of disease  is  provided  by  studies  in  different  animal  models  
where  blockade    of   ICAM-1  reduces  inflammatory  cell  accumulation. 
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Chemokines and Cytokines 
Many  of  the  respiratory  viruses,  but  especially  RSV,  can  affect  the  
respiratory  epithelium,  triggering  the  release  of  both   eosinophil 
chemoattractants  (eg, Rantes)  and  IL-6,  IL-8,  GM-CSF,  and  macrophage 
inflammatory  protein  (MIP-1alpha) .  In  a  recent  study  of  RSV-stimulated 
neutrophils,  the  release  of  IL-8  and  MIP-1 beta  and  neutrophil  
degranulation were  demonstrated.[9]  Rantes  is  a  potent  chemoattractant  for  
eosinophils,  while  GM-CSF  is  important  for  eosinophilopoiesis.  IL-8  will  
lead  to  the influx  of  neutrophils,  which,  in  turn,  can  further  contribute  to  
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inflammation by  the  release  of  their  stored/de  novo  synthesized  
chemokines  and  granular enzymes. 
MIP-1 alpha  stimulates  eosinophil  and   basophil  chemotaxis  and  
degranulation,  which  leads  to  further  recruitment  of  these  cells  and  the 
subsequent  release  of  eosinophil  cationic  proteins  (ECP)  and  histamine      
into  the  airways. 
MIP-1  beta  is  a  member  of  the  c-c  chemokine  family.  Its  function  
is         not  fully  defined,  but  it  appears  capable  of  stimulating  antigen-
specific Th2  lymphocyte  proliferation  and  upregulating  the  costimulatory  
molecule CD80  on  antigen-presenting  cells.  Of  note,  ECP,  eosinophil  
neurotoxin,  and histamine  have  been  identified  in  the  respiratory  secretions  
of  bronchoalveolar  lavage  fluid  of  infants  with  RSV  bronchiolitis.  
Neutrophils,  IL-8,  and  neutrophil  myeloperoxidase  have  also  been  found  
in  the  respiratory  secretions  of  children  with  viral-induced  asthma. 
Another  inflammatory  mechanism  possibly  involved  in  the  
development  of asthmatic  symptoms  may  be  the  increase  in  production  of  
IL-11  by  epithelial  cells  following  viral  infection.  In  children  with  viral  
upper  RTI  and  in  those  with  wheezing,  IL-11  levels  are  elevated  in  nasal  
secretions. Administration  of  recombinant  IL-11  into  the  lungs  of  mice  
results  in increased  airway  responsiveness  to  methacholine.  The  role  IL-11  
plays  in virus-induced  lung  disease  remains  to  be  determined. 
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Eosinophils  and  M2  Receptor  Dysfunction 
The  inflammatory  response  elicited  by  viral  RTI  and  particularly  the 
accumulation  of  eosinophils  most  likely  play  essential  roles  in  the 
development  of  wheezing  during  acute  infection.  The  study  authors  have 
recently  reported  in  a  murine  model[10,11]  that  the  eosinophilic  component     
of  the  inflammatory  response  to  acute  RSV  infection  and  the  associated 
development  of  AHR  to  methacholine  provocation  are  dependent  on  the 
presence  of  IL-5.  Blockade  of  the  eosinophil  adhesion  molecule  VLA-4 
prevented  both  eosinophil  migration  into  the  airways  and  the  associated 
development  of  AHR.  These  data  extend  some  of  the  clinical  observations 
that  development  of  RSV –  induced  AHR  is  associated  with  the  presence    
of  eosinophils  and  may  be  dependent  on  this  eosinophilic  response. 
Dependence  of  virus-induced  AHR  on  IL-5  has  also  been  reported  
in  a guinea  pig  model  of  influenza  infection.  Studies  in  guinea  pigs  
revealed  a mechanism  by  which  eosinophils  could  influence  airway  tone  
and  reactivity. Cationic  proteins  released  by  eosinophils  are  capable  of   
binding  to presynaptic  M2  muscarinic  receptors  on  postganglionic  
parasympathic     airway  nerves.  The  resulting  blockade  interrupts  an  
inhibitory  feedback mechanism,  resulting  in  increased  release  of  
acetylcholine  and  in  increased airway  muscle  tone  and  reactivity.  This  
mechanism  has  been  demonstrated both  in  models  of  allergic  sensitization  
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and  following  acute  viral  infection. Parainfluenza  neuraminidase  can  also  
bind  to  M2  muscarinic  receptors directly  and  may  be  responsible  for  
effects  described  in  the  absence  of eosinophilic  inflammation.  In  addition,  
viral  infection  and  interferon-gamma downregulate  M2  receptor  gene  
expression. 
Noninflammatory  Mechanisms   in   Virus-Induced   Wheezing 
Additional  noninflammatory  mechanisms  may  contribute  to  the  
development of  wheezing  following  viral  RTI.  Viral  infection  of  
respiratory  epithelium results  in  reduced  nitric  oxide  production  associated  
with  AHR  in  guinea pigs.  Nitric  oxide  is  the  putative   bronchodilator  
agonist  of  the  non -  adrenergic,  noncholinergic  inhibitory  (NANCi)  system.  
This  system  can   be defective  during  and  after  respiratory  viral  infection  
resulting  in  AHR,  as demonstrated  in  a  study  of  RSV  infection  of  cotton  
rats.[12] 
A  reduced  barrier  function  of  the  respiratory  epithelium  may  expose  
sensory C  fibers  to  enhanced  stimulation.  This  results  in  the  release  of  
neuropeptides,  such  as  substance  P  and  neurokinin  A,  both  agonists  of     
the nonadrenergic,  noncholinergic  activating  system;  further,  it  induces  a 
brainstem  reflex  leading  to  bronchoconstriction.  Neuropeptides  can  also 
contribute  to  airway  obstruction  by  causing  increased  leukotriene  
synthesis, release  of  mast  cell  mediators,  and  increased  mucus  secretion.  
 
 
13
In addition, infected  epithelial  cells  produce  smaller  amounts  of  neutral  
endopeptidase,   an  enzyme  that  degrades  neuropeptides.  The  role  of  
sensory  C  fibers  in virus - induced  asthma  exacerbations  in  humans  
remains  controversial. Bradykinin  provocation  following  experimental  
rhinovirus  infection  in   mild asthmatics  does  not  result  in  increased  
bronchial  hyperresponsiveness. Bradykinin  is  a  strong  stimulator  of  sensory  
C  fibers  and  may  be  expected to  cause  increased  bronchial  
hyperresponsiveness  if  this  system  plays  a  major  part  in  virus - induced  
asthma. 
Persistence  of  Infection 
At  present,  the  mechanisms  by  which  acute  respiratory  tract  virus  
infection can  affect  the  development  of  asthma  long  after  the  infection  has  
resolved are  unclear.  Some  of  the  pathologic  changes  may  simply  persist  
for  long periods  after  the  acute  infection.  A  defect  in  NANCi  function  
has  been demonstrated  to  last  for  up  to  24  weeks  following  RSV  
infection  in  ferrets. Persistence  of  infection,  resulting  in  chronic  alterations  
of  epithelial  cell function  and  chronic  inflammation,  is  supported  by  
findings  in  guinea  pigs and  calves  where  RSV  antigen  can  be  detected  in  
the lung  6  and  12  weeks after  the  infection.  In  guinea  pigs,  this  
persistence  is  associated   with persistent  AHR. 
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Interactions  Between  Viral  RTI  and  Allergic  Sensitization 
To  define  potential  mechanisms  of  interaction  between  viral   RTI   
and allergic  sensitization  to  inhaled  allergens,  a  number  of  rodent  models  
have been  developed.  The  majority  of  these  models  showed  increased  
allergic sensitization  following  respiratory  virus  infection,  resulting  in  
eosinophilic airway  inflammation  and  AHR.  In  some  of  these  models,  
animals  were     first  exposed  to  allergen  during  the  acute  infection  phase  
followed  by subsequent  allergen  challenges,  resulting  in  increased  allergic  
sensitization with  elevated  serum  levels  of  allergen – specific  IgE. 
In  these  experimental  approaches,  enhanced  allergic  sensitization  
was potentially  due  to  increased  allergen  uptake  across  inflamed  mucous 
membranes.  Indeed,  in  both  a  guinea  pig  and  a  mouse  model,  exposure       
to  ovalbumin  aerosol  caused  increased  levels  of  serum  ovalbumin  if 
administered  during  acute  virus  infection. 
Schwarze  and  colleagues[10]  reported  on  a  murine  model  of   RSV  
infection and   subsequent  sensitization  to  aerosolized  ovalbumin.  In  this   
model, exposure  to  allergen  over  10  days  was  begun  only  after  the  
resolution  of  the  acute   (RSV)   infection.  This  resulted  in  enhanced  
responses  to  allergen and,  as  a  consequence,  airway  inflammation  with  the  
influx  of  neutrophils and  eosinophils.  This  was  associated  with  altered  
airway  responsiveness  to inhaled  methacholine. 
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In  contrast  to  many  of  the  models  discussed  above,  allergen – 
specific  IgE serum  levels  were  not  higher  in  the  group  that  was  infected  
with  RSV  prior to  allergic  sensitization.  This  may  indicate  that  
mechanisms  other  than increased  allergen  uptake  are  likely  responsible  for  
the  effects  of  RSV infection  on  the  subsequent  exposure  to  allergen.  As  
demonstrated, sensitization  following  acute  RSV  infection  triggers  
eosinophilic   inflammation  and  associated  AHR.  Anti-IL-5  treatment  during  
the  allergen exposure  phase  prevents  lung  eosinophilia  and  the  
development  of  AHR. 
Influenza  and  lung  function 
   
   More  recent  attention  has  focused  on  the  pathophysiology  of  
influenza virus  infections.  It  has  long   been  appreciated  that  individuals  
with  underlying  chronic  obstructive  pulmonary  disease  are  susceptible to  
serious, life-threatening  pulmonary  complications  of  influenza  infection.[13]  
Moreover, these  cases  represent  only  a  small  minority  of  the  estimated   20   
percent  to 50  percent  of  the  population  at  risk  who  are  infected  during  a  
pandemic. 
 
       Previous  studies  have  suggested  that  pulmonary  function  abnormalities 
frequently  follow  influenza  infection,  even  in  the  absence  of  
pneumonia.[14]  For several  sequential  years,  they  have  studied  airway  
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mechanics  in  groups  of  otherwise  healthy  young  adults  with  
nonpneumonic  naturally  acquired influenza  A  (H3N2)  infection.  
 
During  the  initial  three  weeks  following  onset  of  symptoms,  
subjects demonstrated  frequency  dependence  of  total  pulmonary  
resistance.[15] This  finding  suggests  the  presence  of  uneven  airway   time  
constants, and  they  theorized  that  a  generalized  increase  in  flow  resistance  
in   peripheral  airspaces  could  result  in  this  degree  of  frequency  
dependence  of  resistance.[16]  As  was  noted  with  other  viral  infections,  
these  mechanical abnormalities  persisted  beyond  the  period  of  symptomatic  
illness. 
 
      In  a  subsequent  epidemic,  they  were  able  to  further  evaluate   
peripheral airway  mechanics  in  uncomplicated  influenza  infection  by  
demonstrating diminished  density – dependent  forced  flow  rates  in  
volunteers  with  naturally acquired  illness[17]  Again,  these  abnormalities  
persisted  for  some  three   to  five  weeks  following  onset.  Furthermore,  
when  atopic   subjects  were compared  to  normals,  no  difference  in  density 
– dependent   flow  rates  was observed,  suggesting  that  these  abnormalities  
were  not  related  to  pre-existing abnormal  airway  sensitivity. 
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       As  compared  to  the  other  viruses  influenza  virus  induced  pulmonary  
function  alterations  tends   to  persist  for   longer  period  even  upto  one  
year. 
 Currently,  there  is  much  interest  in  the  development  of   live  
vaccines  against  respiratory  viruses,  especially  influenza.[45]   Since  
prolonged  peripheral airway  dysfunction  is  a  common  sequelae  to  naturally 
acquired infection, evaluation  of  various  candidate  vaccines logically should 
include some physiologic  testing.  Several  such  studies  have  been  done,  and  
although results  are  somewhat  variable,  there  is, at present, no evidence that 
live influenza  virus  vaccines  have  serious  deleterious  effect  on  lung  
funclion.[46] [47] [51] 
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VIRAL  INFECTIONS  AND  DISEASED  LUNG    
         Historically,  bacteria  have  been  considered  the  main  infectious  cause  
of COPD  exacerbations.[18]  A  growing  body  of  evidence,  however,  
implicates viral  upper  respiratory  tract  infections  (URIs)  as  the  
predominant  risk  factor associated  with  exacerbations  of  
COPD.[19]  Approximately  40-60%  of  all COPD  exacerbations  are  
associated  with  URIs. [20,21,22]  This  figure  may actually  underestimate  the  
true  impact  that  viruses  have  on  individuals  with COPD.  For  instance,  it  
is  well  recognized  clinically  that  upper  respiratory tract  cold  symptoms  
often  precede  COPD  exacerbations  by  days  to  weeks. Therefore,  clinical  
studies  that  sample  for  viruses  during  a  COPD exacerbation   fail  to  detect  
virus  despite  using  highly  sensitive  PCR technology. 
       The  major  respiratory  viruses  associated  with  exacerbations  of  COPD   
are  as  follows:[48] 
1. rhinovirus; 
2. coronavirus; 
3. influenza; 
4. parainfluenza; 
5. adenovirus; 
6. respiratory syncytial virus (RSV). 
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          The  prevalence  of  each  of  these  viruses  can  vary  widely  depending   
on  geography  and  local  epidemiologic  trends.  For  example,  a  recent  Hong 
Kong  study [23]  found  that  influenza  was  the  most  common  virus  identified  
in  patients  hospitalized  with  COPD  exacerbations[49] [50].  The  high  
prevalence  of influenza  in  that  study,  however,  may  have  been  due  to  the  
relatively  low influenza  vaccination  rate  (40.3%)  among  study  participants.  
By  contrast ,  the  relatively  low  prevalence  of  influenza  seen  in  a  
prospective  cohort  from a  London  outpatient  clinic [24]  was  most  likely  
attributable  to   the  74% influenza  vaccination  rate  among  that  population. 
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SWINE  FLU 
           
           Influenza  A  (H1N1)  virus  is  a  subtype  of  influenza  A  virus  and   
was  the  most  common  cause  of  human  influenza  (flu)  in  2009.  Some  
strains of  H1N1  are  endemic  in  humans   and  cause  a  small  fraction  of  
all  influenza-like  illness   and  a  small  fraction  of  all  seasonal   influenza. 
H1N1  strains  caused  a  few  percent  of  all  human  flu  infections  in  2004–
2005.[25]  
          Swine  influenza  (also  called  swine  flu,  hog  flu,  or  pig  flu)  is  an  
infection by  any  one  of  several  types  of  swine  influenza  virus.  Swine  
influenza  virus (SIV)  is  any  strain  of  the  influenza  family  of  viruses  that  
is  endemic  in  pigs.  As  of  2009,  the  known  SIV  strains  include  influenza  
C  and  the subtypes  of  influenza  A  known  as  H1N1,  H1N2,  H3N1,  H3N2,  
and   H2N3.[49] 
          Swine  influenza  virus  is  common  throughout  pig  populations 
worldwide.  Transmission  of  the  virus  from  pigs  to  humans  is  not  
common and  does  not  always  lead  to  human  influenza,  often  resulting  
only  in  the production  of  antibodies  in  the  blood.  If  transmission  does  
cause  human influenza,  it  is  called  zoonotic  swine  flu.  People  with  regular  
exposure  to pigs  are  at  increased  risk  of  swine  flu  infection.   
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          Pigs  experimentally  infected  with  the  strain  of  swine  flu  that  is  
causing   the  current  human  pandemic  showed  clinical  signs  of  flu  within 
four  days,  and  the  virus  spread  to  other  uninfected  pigs  housed  with  the 
infected  ones.[26] 
BACKGROUND 
          The  epidemiology  of  pandemic  (H1N1)  2009  virus  infection  to  date 
indicates  that  children  and  young  adults  have  had  the  highest  attack  rates.   
A  wide  clinical  spectrum  of  disease  ranging  from  non-febrile,  mild  upper 
respiratory  tract  illness,  febrile  influenza  like  illness  (ILI)  to  severe  or  
even fatal  complications,  including  rapidly  progressive  pneumonia  has  been 
described.  The  most  commonly  reported  symptoms  have  included 
cough,  fever,  sore  throat,  muscle  aches,  malaise,  and  headache.  Some   
patients  have  experienced  gastrointestinal  symptoms  (nausea,  vomiting,   
and/or  diarrhoea). 
         
           Approximately  10-30%  of  hospitalized  patients  in  some  countries  
have required  admission  to  intensive  care  units  (ICU).  Critically  ill  
patients include  those  who   experienced  rapidly  progressive  lower  
respiratory  tract disease,  respiratory  failure,  and  acute  respiratory  distress  
syndrome  (ARDS) with  refractory  hypoxemia.  Other  severe  complications  
have  included secondary  invasive  bacterial  infection,  septic  shock,  renal  
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failure,  multiple organ  dysfunction,  myocarditis,  encephalitis,  and  
worsening  of underlying   chronic  disease  conditions  such  as  asthma,  
chronic  obstructive pulmonary  disease  (COPD),  or  congestive  cardiac  
failure. 
 
RISK FACTORS FOR SEVERE DISEASE 
           From  pandemic  (H1N1)  2009  virus  infection  reported  to  date  are 
considered  similar  to  those  risk  factors  identified  for  complications  from 
seasonal  influenza.   
These  include  the  following  groups: 
•  Infants  and  young  children,  in  particular  <2  years 
•  Pregnant  women 
•  Persons  of  any  age  with  chronic  pulmonary  disease  (e.g.  asthma,  
COPD) 
•  Persons  of  any  age  with  chronic  cardiac  disease  (e.g.  congestive  cardiac  
failure) 
•  Persons  with  metabolic  disorders  (e.g.  diabetes) 
•  Persons  with  chronic  renal  disease,  chronic  hepatic  disease,  certain 
neurological  conditions  (including  neuromuscular,  neurocognitive,  and  
seizure disorders), 
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•  Hemoglobinopathies,  or  immunosuppression,  whether  due  to  primary 
Immunosuppressive  conditions,  such  as  HIV  infection,  or  secondary 
conditions,  such  as  immunosuppressive  medication  or  malignancy, 
•   Children  receiving  chronic  aspirin  therapy 
•   Persons  aged  65  years  and  older. 
            A  higher  risk  of  severe  complications  from  pandemic  (H1N1)  2009 
virus  infection  has  also  been  reported  in  individuals  who  are  obese 
(particularly  in  those  who  are  morbidly  obese)  and  among  disadvantaged  
and indigenous  populations. 
          On  average,  about  1/2  of  hospitalized  patients  have  had  at  least  one  
or  more  underlying  medical  conditions.   However,  about  1/3  of  patients  
with very  severe  illness  admitted  to  ICU  were  previously  healthy  persons. 
          The  incubation  period  appears  to  be  approximately  2-3  days ,  but  
could  range  up  to  7  days. 
CASE DESCRIPTION 
Uncomplicated influenza 
•  ILI  symptoms  include:  fever,  cough,  sore  throat,  rhinorrhea,  headache, 
muscle  pain,  and  malaise,  but  no  shortness  of  breath  and  no  dyspnoea. 
Patients  may  present  with some  or  all  of  these   symptoms. 
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      Gastrointestinal  illness  may  also  be  present,  such  as  diarrhoea  and/or 
vomiting,  especially  in  children,  but  without  evidence  of  dehydration. 
Complicated or severe influenza 
• Presenting  clinical  (e.g.  shortness  of  breath / dyspnoea,  tachypnea,  
hypoxia) and/or   radiological  signs  of  lower  respiratory  tract  disease  (e.g.  
pneumonia), central  nervous  system  (CNS)  involvement  (e.g .  
encephalopathy, encephalitis),  severe  dehydration,  or  presenting  secondary  
complications,   such  as  renal  failure,  multiorgan  failure,  and  septic  shock.  
Other complications  can  include  rhabdomyolysis  and  myocarditis. 
• Exacerbation  of  underlying  chronic  disease,  including  asthma,  COPD, 
chronic  hepatic  or  renal  failure,  diabetes,  or  other  cardiovascular  
conditions. 
•  Any  other  condition  or  clinical  presentation  requiring  hospital  admission  
for  clinical management. 
•  Any  of  the  signs  of  disease  progression  listed  below. 
Signs and symptoms of progressive disease 
            Patients  who  present  initially  with  uncomplicated   influenza  may 
progress  to  more  severe  disease.  Progression  can  be  rapid  (i.e.  within  24 
hours ).  The  following  are  some  of  the  indicators  of  progression,  which 
would  necessitate  an  urgent  review  of  patient  management: 
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•  Symptoms  and  signs  suggesting  oxygen  impairment  or  cardiopulmonary 
insufficiency: 
- Shortness  of  breath  (with  activity  or  at  rest ),  difficulty  in  breathing,  
turning  blue,  bloody  or  coloured  sputum,  chest  pain,  and  low  blood  
pressure; 
- In  children,  fast  or  laboured  breathing;  and 
- Hypoxia,  as  indicated  by  pulse  oximetry. 
• Symptoms  and  signs  suggesting  CNS  complications: 
- Altered  mental  status,  unconsciousness,  drowsiness,  or  difficult  to  
awaken and  recurring  or  persistent  convulsions  (seizures),  confusion,  severe  
weakness,  or  paralysis. 
• Evidence  of  sustained  virus  replication  or  invasive  secondary  bacterial 
infection  based  on  laboratory  testing or clinical  signs  (e.g.  persistent  high 
fever  and  other  symptoms  beyond  3  days). 
• Severe  dehydration,  manifested  as  decreased  activity,  dizziness,  decreased 
urine  output,  and  lethargy.  
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PREGNANCY  AND  H1N1  INFLUENZA 
Pregnant  women,  especially  those  with  co-morbidities,  are  at  
increased risk  for  complications  from  influenza  virus  infection.  Influenza  
in  pregnancy is  associated  with  an   increased  risk  of  adverse  pregnancy  
outcomes,  such  as spontaneous  abortion,  preterm  birth,  and  fetal  distress.  
Consequently,  pregnant  women  with  suspected  or  confirmed  pandemic  
(H1N1)  2009  virus infection  warrant  closer  observation  and  early  antiviral  
treatment  ( see  below section  on  antivirals).  Paracetamol  (acetaminophen)  
is  recommended  to  ease fever  and  pain  in  pregnant  women,  as  non-
steroidal  anti-inflammatory  drugs  (NSAIDs),  including  aspirin,  are  
associated  with  fetal  risks  and  maternal bleeding  and  are,  therefore,  
contraindicated  in  pregnancy. 
 
 
 
 
 
 
 
 
 
 
27
GUIDELINES  ON  CATEGORIZATION  OF  INFLUENZA  A  H1N1 
CASES  DURING   SCREENING  FOR  HOME  ISOLATION,  TESTING 
TREATMENT,  AND  HOSPITALIZATION[27] 
 
               In  order  to  prevent  and  contain  outbreak  of   Influenza-A  H1N1 
virus  for   screening,  testing  and  isolation  following  guidelines  are  to  be 
followed: 
              At   first  all  individuals  seeking   consultations  for  flu  like  
symptoms 
should  be  screened  at  healthcare  facilities  both  Government  and  private  or  
examined  by  a  doctor  and  these  will  be  categorized  as  under: 
Category- A 
    Patients  with  mild  fever  plus  cough  /  sore  throat  with  or  
without 
body  ache,  headache,  diarrhoea  and  vomiting  will  be  categorized  as 
Category-A.  They  do  not  require  Oseltamivir  and  should  be  treated 
for  the  symptoms  mentioned  above.  The  patients  should  be  monitored 
for  their  progress  and  reassessed  at  24  to  48  hours  by  the  doctor. 
  No  testing  of  the  patient  for  H1N1  is  required. 
  Patients  should  confine  themselves  at  home  and  avoid  mixing  up 
with  public  and  high  risk  members  in  the  family. 
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Category-B 
 
(i)  In  addition  to  all  the  signs  and  symptoms  mentioned  under 
Category-A,  if  the  patient  has  high  grade  fever  and  severe  sore 
throat,  may  require  home  isolation  and  Oseltamivir; 
 
(ii)  In  addition  to  all  the  signs  and  symptoms  mentioned  under 
Category-A,  individuals  having  one  or  more  of  the  following 
high  risk  conditions  shall  be  treated  with  Oseltamivir: 
 
    Children  with  mild  illness  but  with  predisposing  risk 
factors. 
  Pregnant  women; 
  Persons  aged  65  years  or  older; 
  Patients  with  lung  diseases,  heart  disease,  liver  disease, kidney  
disease,  blood  disorders,  diabetes,  neurological  disorders,  cancer  and 
HIV/AIDS; 
  Patients  on  long  term  cortisone  therapy. 
  No  tests   for  H1N1  is   required  for  Category-B  (i)  and  (ii). 
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  All  patients  of  Category-B  (i)  and  (ii)  should  confine  themselves  
at  home  and  avoid  mixing  with  public  and  high  risk  members  in  the  
family. 
 
Category-C 
 
            In  addition  to  the  above  signs  and  symptoms  of  Category-A  and  
B,  if  the  patient  has  one   or  more  of  the  following: 
  Breathlessness,  chest  pain,  drowsiness,  fall  in  blood  pressure, 
sputum  mixed  with  blood,  bluish  discolouration  of  nails; 
  Children  with  influenza  like  illness  who  had  a  severe  disease  as 
 manifested  by  the  red  flag  signs  (Somnolence,   high  and  persistent  fever, 
inability  to  feed  well,  convulsions,  shortness  of  breath,  difficulty  in  
breathing,  etc). 
     Worsening  of  underlying  chronic  conditions. 
 
All  these  patients  mentioned  above  in  Category-C  require  testing,  
immediate 
hospitalization  and  treatment. 
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H1N1  INFLUENZA   A  GLOBAL  BURDEN 
 
The  2009  flu  pandemic  was  a  global  outbreak  of  a  new  strain  
of  H1N1 influenza  virus,  often  referred  to  as  "swine flu". [28]  First  
described  in  April 2009 ,  the  virus  appeared  to  be  a  new  strain  of  H1N1  
which  resulted  when a  previous  triple  reassortment  of  bird,  pig,  and  
human  flu  viruses  further combined  with  a  Eurasian  pig  flu  virus.[29] 
The  outbreak  began  in  the  state  of  Veracruz,  Mexico,  with  evidence  that 
there  had  been  an  ongoing  epidemic  for  months  before  it  was  officially 
recognized  as  such.[30]  In  June,  the  World  Health  Organization  (WHO) 
and  US  Centers  for  Disease  Control  (CDC)  stopped  counting  cases  and 
declared  the  outbreak  to  be  a  pandemic.[31]    
 
Currently,  there  are  14,286  confirmed  deaths  worldwide.  This  figure  
is  a sum  of  confirmed  deaths  reported  by  national  authorities;  the  WHO  
states that  total  mortality  (including  deaths  unconfirmed  or  unreported)  
from  the new  H1N1  strain  is  "unquestionably  higher".[32] 
The  pandemic  began  to  taper  off  in  November  2009, [33]  and  by  
May  2010, the  number  of  cases  was  in  steep  decline. [32][34][35][36]  On  10  
August  2010, the  Director – General  of  the  World  Health  
Organization,  Margaret  Chan, announced  the  end  of  H1N1  
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pandemic.[37]  Chan  noted  that  the  H1N1 pandemic  could  have  been  much  
worse.  According  to  the  latest  World Health  Organization  statistics,  the  
virus  has  killed  more  than  18,000  people since  it  appeared  in  April  
2009,[38]  approximately  4%  of  the  250,000 to  500,000  annual  influenza  
deaths.[39] 
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                                 MATERIALS  AND  METHODS  
SETTINGS  
       Outpatient  clinics  at 
•   Institute  of   Internal  Medicine  
 
  Madras  Medical  college  and  Government  General  Hospital 
  
  Chennai – 600003 
 
•   Department  of   Thoracic  Medicine  
 
  Madras  Medical  college  and  Government  General  Hospital 
  
  Chennai – 600003 
 
 ETHICAL COMMITEE APPROVAL 
         Obtained  
 
 STUDY  DESIGN 
         Cross sectional  study  design 
 
 PERIOD  OF  STUDY 
       September  2009  to  October  2010 
 
SAMPLE  SIZE 
       50  cases 
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CONSENT 
     Informed  consent  was  obtained  from  all  the  patients  participating  in 
the  study. 
 
INCLUSION  CRITERIA 
      Patients  who  were  treated  for  H1N1  influenza  in  Institute  of  
 Internal  Medicine  in  Government  General  Hospital,  Chennai 03, 
during  the  year  2009. 
 
EXCLUSION CRITERIA 
       
1. Patients  with  a  history  URI  or  LRI  within  previous  6 to 8 
weeks  duration 
2. Smokers,  
3. Patients  who  are  not  willing   for  spirometry  testing.  
.  
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METHODOLOGY 
  
         Out  of  58  patients  initially  enrolled  for  the  study,  50  patients  were  
selected.  Others  were  excluded  as  per  the  exclusion  criteria. 
 
         Patients  previous  records  were  reviewed  to  classify  them  according  
to  WHO  severity  classification. 
 
        Patients  were  assessed  for  the  presence  symptomatology  suggestive  
of   air  way  diseases  like  cough,  expectoration,  breathlessness,  wheeze,     
limitation  of  activities  and  exacerbation  of  their  underlying  illness . 
 
      They  have  also  examined  for  the  presence  of  signs of  airway  diseases 
like  tachypnea,  cyanosis,  wheeze  or  rhonchi. 
 
     Subsequently  the  patients  were  subjected  to  pulmonary  function  test  by   
spirometry.        
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SPIROMETRY 
    
     Spirometry  was  performed  using  standard  equipment  at  the  outpatient   
department  of   Thoracic  Medicine.  Airway  indices  like  
FEV1,  FVC,  FEV1/FVC  and  PEF were  recorded  in these  patients. 
 
      The performance  of  spirometry  while  seated  upright  in  a  chair  is  
preferable  to standing  as  this  is  the  most  stable  position  should  the  patient  
experience dizziness  during  the  test.  The  seated  position  is  also  preferable  
for patients  with  urinary  incontinence  who  may  otherwise  limit  the  
expiratory effort. 
The  key  steps  are  to  urge  the  patient  to:[40][41][42] 
• Breathe  in  fully  (the  lungs  must  be  absolutely  full). 
• Seal  the  lips  around  the  mouthpiece  and  immediately…. 
• Blast  the  air  out  as  fast  and  as  far  as  possible  until  the  lungs  are 
completely  empty. 
• Repeat  the  test  until  three  acceptable  and  reproducible  results  are 
obtained  (up  to  a  maximum  of   8  efforts) 
• The  highest  FEV1  and  FVC  should  be  reported,  even  if  they  come 
from  separate  blows. 
 
 
36
Spirometry  requires  maximal  effort  from  the  patient  and  it  takes  time to  
perform  quality  spirometry.  As  it  was  essential  the  procedure  was  
carefully  and  clearly  explained  to  the  patient  and  motivated   to  perform  
maximally  and  completely.  The  volume  and  flow  parameters  measured  are 
defined  in  terms  of  maximal  effort  and  maximal  exhaled  volume.   
        While  it  is  not  mandatory  to  use  nose  clips  to  prevent  loss  of  
measured volume  through  the  nose ,  their  use  is  sometimes  of   benefit. 
Activities that should preferably be avoided prior to lung function testing 
Smoking within at least 1 h of testing 
Consuming alcohol within 4 h of testing 
Performing vigorous exercise within 30 min of testing 
Wearing clothing that substantially restricts full chest and abdominal expansion 
Eating a large meal within 2 h of testing 
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Results 
Acceptable  results  are  those  that  were  initiated  at  full  lung  inflation,  and 
with  maximum  expiratory  effort (eg  no  hesitation  at  the  start  and  no 
pauses  throughout  the  blow)  until  no  more  air  can  be  expired.  The  
results  are  reproducible  if  there  is  less  than  200ml  variation  in  FEV1  and 
FVC  between  the  two  best  blows. 
Conditions where suboptimal lung function results  are likely 
Chest or abdominal pain of any cause 
Oral or facial pain exacerbated by a mouthpiece 
Stress incontinence 
Dementia or confusional state 
Severity  of  the  airway  obstruction: 
 
• Mild  - FEV1  > 80%  of  predicted 
• Moderate   - FEV1  50 – 80%  of  predicted 
• Severe  -  FEV1  < 50%  of  predicted    
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CLINICAL  PRESENTATION 
 
DISEASE NO OF 
PATIENTS 
RECURRENT
      RTI 
  WHEEZE     TOTAL 
 
   B.ASTHMA 
 
        05 
 
        04 
 
         04 
 
        04 
 
       COPD 
 
        04 
 
        02 
 
         02 
 
        02 
 
TUBERCULOSIS 
 
        02 
 
-  
 
          - 
 
        - 
 
   PREGNANCY 
 
        02 
 
         - 
 
          - 
 
        - 
 
    NORMAL 
 
        37 
 
         - 
 
          - 
 
        - 
 
         Non  of  the  patients  with  normal  lung  prior  to  H1N1  influenza  had   
experienced  any  increase  in  the  incidence   of  respiratory  infections  or 
new  onset  of  breathlessness  or  wheeze. 
 
        Patients  who  was  treated   for   pulmonary  tuberculosis  previously 
and  females  who  were  pregnant  during  the  influenza  infection  have   
not  developed  any  new  symptoms. 
 
         Out   of  five  bronchial  asthma  patients  who  participated  in  the  
study  four   patients  experienced  increase  in  the  episodes   of   acute   
exacerbation  of  their  symptoms. 
         Out  of  four  COPD  patients  in  the  study  two  patients  had 
more   frequent  exacerbation  of  their  symptoms. 
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BRONCHIAL  ASTHMA  AND  H1N1  INFLUENZA 
 
 
Patients 
 Age/ 
   Sex 
  No of 
years of  
illness 
Exacerbations 
/yr before  
H1N1 
 H1N1
severit
y 
Exacerbatio
ns  
after H1N1 
No of 
hospital 
admission 
spirometry
 
Pt – 1  
 
15/M 
 
 6 years 
 
         1 
 
     B 
 
        4 
 
      2 
Obstructiv
e pattern 
 
Pt – 2 
 
29/M 
 
15 years 
 
         2 
 
     C 
 
        4 
 
      4 
Obstructiv
e pattern 
 
Pt – 3  
 
20/M 
 
 8 years 
 
         1 
 
     B 
 
        2 
 
      1 
Obstructiv
e pattern 
 
Pt – 4  
 
21/F 
 
 8 years 
 
         1 
 
     B 
 
        3 
 
      1 
Obstructiv
e pattern 
 
Pt – 5  
 
31/F 
 
11 years 
 
         1
 
     B
 
-  
 
-  
Obstructiv
e pattern 
 
 
        Four  patients  experienced  a  significant  increase  in episodes  of   acute 
exacerbations  and  all  the  patients  who  experienced  increase  in  acute 
exacerbations  required  at  least  one  hospital  admission  for  the  management 
of  their  symptoms. 
 
        Patient  who  had  severe  disease  had  severe  grade  of  infection  during 
H1N1  influenza  and  had  experienced  4  episodes  of  acute  exacerbation  of 
bronchial  asthma. 
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COPD  AND  H1N1  INFLUENZA 
      
 
S. 
NO 
 
Age/ 
Sex 
  No  
   of 
years 
   of  
illness 
Exacerbations/
yr before  
H1N1 
 H1N1 
severity 
Exacerbations 
after H1N1 
No of 
hospital 
admission 
spirometry 
 
1. 
53/ 
M 
 
   4 
 
        2 
 
     B 
 
       2 
 
      - 
Obstructive 
pattern 
 
2. 
53/ 
M 
 
   6 
 
        4 
 
     B 
 
       6 
 
      2 
Obstructive 
pattern 
 
3. 
36/ 
M  
 
   2 
 
        1 
 
     B 
 
       3 
 
      1 
Obstructive 
pattern 
 
4. 
49/ 
M  
 
   2 
 
        1 
 
     B 
 
       1 
 
      - 
Obstructive 
pattern 
 
 
                Out  of  four  patients  two  had  increase  in  the  episodes  of  acute  
exacerbation  of  their  symptoms  and  both  of  them  required  hospitalization 
at  least  once. 
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EFECTS  OF  H1N1  INFLUENZA  ON  NORMAL  LUNG   
 
 
 
Category 
      A 
Category 
      B 
Category 
       C 
Total  
Patients 
Symptoms spirometry
   
  Male  
 
    19 
 
     02 
 
    02 
 
     23 
 
     Nil  
Normal 
pattern 
 
 Female  
 
    11 
 
     05 
 
     - 
 
     15 
 
     Nil  
Normal 
pattern 
 
          All  the  patients   who  were  treated  for  H1N1  influenza  had   no   
new  respiratory  symptoms  like  breathlessness  or  wheeze  independent 
of  severity  of  their  H1N1  infection.  
  
         Two  females  who  were  pregnant  during  H1N1  infection   had 
normal  ante  partum   period  and  normal  child  birth  after  treatment  
with  oseltamavir.          
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          DISCUSSION 
 
         Summary 
 
            This  is  a  cross  sectional  study  of  patients  who  were   
previously   diagnosed  positive   for  H1N1  influenza   and  
treated  in  government  general   hospital.  Totally  58  patients  
were  participated  in  the  study  out  of  them  50  were   selected  
based  on  the  exclusion   criteria   and   subjected  to  retrospective  
history   regarding  the  respiratory  symptoms,  clinical  
examination  of  the  respiratory  system  and  spirometry.  All  the   
patients  in  this  study   were  had  the  disease   (H1N1  influenza)  
one  year  prior  to  the  study. 
 
         As  compared   to  the  previous  studies   which  was   conducted  
during  the   H3N2  influenza[43]   patients   were    had   an  interval  
of   one  year   between  the  illness  and   the  study   and  the  
patients  in  that   study  were   tested  for  pulmonary  functions  
along  with  above  measures   they  have  used  oscillatory  
method[44]  for  assessing   airway  resistance. 
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Characteristics  of   the   study  population    
 
    The  age  distribution   of   the   study   population  is  distributed   
widely  from  13 years  to  61  years .  And  the   average  age  of  the  
study  population   in  the  present  study  is   32.92.  Most   of   the  
patients  were  in  the  age  group  between  21  to  40 years  of  age.  
     
    Around  62%  percent  of  the  population  participated  in  the  
population  were  males. 
 
    Out  of  50  patients  participated  in  this  study  five  patients  were 
asthmatics,  four  patients  were   had  COPD,  two  patients  were  
previously  treated  for  pulmonary  tuberculosis  and  two  females  were  
pregnant  during  the  time  of  H1N1  infection. 
 
    Two  pregnant  females  had   normal  ante partum  period  and  normal  
labour. 
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    Patients   with  underlying  lung   disease  experienced  severe  form  of  
lung  disease  when  compared  to  the  people  with  no  underlying  lung  
disease. 
  
    Patients  with  underlying  lung  disease  like  bronchial  asthma  and 
COPD  experienced   increase  in  the  episodes  of  acute  exacerbations  
when  compared  to  pre  H1N1  infection  period. 
 
    People  with  underlying  normal   lung  function  and  with  no  other 
precipitants  does  not  developed  any  new  symptoms  or  any  
derangement  in  lung  functions.       
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CONCLUSION 
 
1.   H1N1  influenza   infection  does  not  produced  any  persistent  
symptoms or  signs of  impaired  pulmonary  fuctions   in  individuals  
who  had  normal  lung  function  prior  to  H1N1  influenza  infection. 
 
2.   Patients  who  had  pulmonary   tuberculosis  and  completed  
treatment  and  no  residual  anatomical  damage also  did  not  have 
persistent  defect  in  lung  functions. 
 
 
3. Patients  with  COPD  and  bronchial  asthma  showed  an  increase   in  
the  frequency  of  acute  exacerbations  after  H1N1  influenza  
infection  which  persisted  more than  a year. 
 Hence  it  may  be  inferred   that  patients  with    diseased  airways  like  
COPD   and  bronchial  asthma   had  severe   disease   during   the   acute  stage   
of  H1N1  influenza  infection  and  are  more  susceptible  for  increased   hyper 
responsiveness  of  the  bronchial   airways  which  may  be  become  persistent. 
 
  
 
 
51
SUGGESTIONS  
 
 Since the patients with  underlying lung diseases like COPD and 
Branchial Asthma  experienced severe infection during the acute phase and had 
persistent deterioration of there underline lung disease after H1N1 influenza  
infection. So this patients should be vaccinated against influenza  infection. 
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ABBREVIATIONS 
 
COPD          – Chronic Obstructive Pulmonary Disease 
RSV    - Respiratory  Syncytial Virus  
ICAM-1  - Intercellular   Adhesion  Molecule 1  
TNF   – Tumor Necrosis Factor 
AHR   – Airway Hyper Responsiveness 
IL            – Interleukin 
GM-CSF  – Granulocyte Monocyte Colony Stimulating Factor 
ECP   – eosinophil  cationic  proteins 
MIP-1alpha – macrophage  inflammatory  protein   
RTI     – Respiratory Tract Infections 
ARDS  – Acute  Respiratory  Distress  Syndrome   
PFT   – Pulmonary Function Test 
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PROFORMA 
 
Name:    Age/Sex:    
Address:      
 
Complaints during H1N1 infection: 
Sore throat                 :         Yes/ No  
Cough with expectoration:  Yes/ No  
Fever                     : Yes/ No       
Breathlessness   : Yes/ No  
Hemoptysis   :          Yes/ No 
Other symptoms  : 
 
Hospital admission           :           Yes/ No 
 Methyl prednisone           :           Yes/ No  
Present complaints; 
Persistent symptoms 
  Cough                    :   Yes/ No             Expectoration:  Yes/ No  
  Breathlessness   :   Yes/ No             Wheeze           :  Yes/ No 
  Limitation of activities   :   Yes/ No   
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  Other symptoms            :     
 
Past History   :   
COPD    : Yes/ No 
Bronchial asthma  : Yes/ No 
Connective tissue disease: Yes/ No 
Tuberculosis  : Yes/ No 
 
Personal History: 
Smoking   :  Yes/ No Duration: 
Occupational exposure to respiratory pollutantants: Yes/ No 
Examination   : 
Cyanosis: Yes/ No                        Pallor: Yes/ No 
Clubbing: Yes/ No 
Respiratory system 
Sings of volume loss       :  Yes/ No 
Auscultation                     : 
Breath sounds    : 
Wheeze                :  Yes/ No            localized / generalized 
Crepitations        :   Yes/ No          
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Investigations        : 
Chest X ray: 
Trachea        : 
Lung fields   : 
 
 
Others          : 
 
 
Complete blood count: 
TC                 : 
DC  :   P:          L:         E: 
ESR  : 
Hb  : 
PCV  : 
Platelets       : 
 
Pulmonary function test: 
Tidal volume           : 
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TLC   : 
FEV1   : 
FVC   : 
FEV1/ FVC  : 
 
 
 
Outcome: 
 
 
Follow-up: 
                                                                               MASTER CHART 
   S.    
  NO 
AGE 
/ SEX 
RECU
RRENT 
      RTI 
WHE
EZE 
B.AST
HMA 
COPD    TB  PREGN
ANCY 
SIGNS     X‐RAY FEV1 FVC FEV1/
FVC 
INFERENC
E  
   1.   23/f      Nil      Nil         Nil     Nil    Nil    Nil    Normal  
  Study 
106 105    105
 
 Normal  
  Study  
   2.  49/m      Nil    Nil       Nil     Nil    Nil    Nil    Normal 
   Study 
 84 76    118  Normal  
  Study  
   3.  55/m      Nil     Nil        Nil    Nil  YES   Nil   Normal 
   Study  
 99 115     91  Normal  
  Study  
   4.  24/m      Nil    Nil       Nil     Nil    Nil    Nil    Normal 
   Study  
100 98    102  Normal  
  Study 
   5.  18/f      Nil     Nil        Nil     Nil    Nil    Nil    Normal 
  Study  
 98 90      109  Normal  
  Study  
   6.  15/m      Nil     Nil        Nil     Nil    Nil    Nil    Normal
  Study  
102 100   102 Normal 
  Study 
   7.  42/m       Nil     Nil        Nil     Nil     Nil    Nil    Normal 
  Study  
100 106     94 Normal 
  Study 
   8.  19/m      Nil     Nil       Nil 
 
   Nil 
 
   Nil 
 
  Nil  
 
 Normal 
  Study  
102 101  101  Normal  
  Study  
   9.   50/m       Nil       Nil       Nil     Nil     Nil     Nil    Normal 
  Study  
 96 98      98  Normal  
study 
  10.  14/m       Nil       Nil       Nil     Nil     Nil     Nil   Normal 
 Study   
100 95   105 Normal 
  Study 
  11. 
 
61/m      Nil       Nil       Nil     Nil     Nil     Nil   Normal
 study 
100 106     94 Normal
 Study 
   S.    
  NO 
AGE 
/ SEX 
RECU
RRENT  
RTI 
WHE
EZE 
B.AST
HMA 
COPD    TB  PREGN
ANCY 
SIGNS     X‐RAY FEV1 FVC FEV1/
FVC 
INFERENC
E  
  12.  50/m     Nil      Nil       Nil    Nil   YES    Nil  Normal
 study 
 98 90    109  Normal  
  Study  
  13.  50/f      Nil     Nil      Nil    Nil    Nil    Nil  Normal 
 Study  
 89 90   99  Normal  
  Study  
  14.  29/m     Nil      Nil       Nil    Nil    Nil    Nil  Normal 
 Study 
 92 100   92 Normal 
 Study 
  15.  22/m      Nil     Nil      Nil     Nil     Nil     Nil   Normal 
 Study 
105 98  107  Normal 
 Study 
  16.    46/f     Nil      Nil       Nil     Nil     Nil     Nil   Normal 
 Study 
 92 96   96 Normal 
 Study 
  17.  14/m     Nil     Nil      Nil    Nil    Nil    Nil  Normal 
 Study 
 98 97  101 Normal 
 Study 
  18.     37/f     Nil      Nil       Nil     Nil     Nil     Nil   Normal 
 Study 
 100 98  102 Normal 
 Study 
  19.    15/f     Nil     Nil      Nil    Nil    Nil    Nil  Normal 
 Study 
  98 90    109 Normal 
 Study 
  20.    27/f     Nil     Nil      Nil     Nil     Nil    YES    Nil   Normal 
 Study 
 99 115   91 Normal 
 Study 
  21.  40/m     Nil     Nil      Nil     Nil     Nil     Nil   Normal 
 Study 
 99 98   101 Normal 
 Study 
  22.   20/f     Nil     Nil      Nil     Nil     Nil     Nil   Normal 
 Study 
 98 102   96 Normal 
 Study 
 23.   13/f     Nil     Nil      Nil    Nil    Nil    Nil  Normal 
 Study 
102 105   97 Normal 
 Study 
   S.    
  NO 
AGE 
/ SEX 
RECU
RRENT 
   RTI 
WHE
EZE 
B.AST
HMA 
COPD    TB  PREGN
ANCY 
SIGNS     X‐RAY FEV1 FVC FEV1/
FVC 
INFERENC
E  
 24.   21/ f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98 92   106 Normal 
 Study 
 25.  30/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
 101 98   103 Normal 
 Study 
 26.   34/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  89 99    90 Normal 
 Study 
 27.  37/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98  97   101 Normal 
 Study 
 28.   19/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
 105 98   107  Normal 
 Study 
 29.   30/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  92 96   96 Normal 
 Study 
 30.  54/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98 97  101 Normal 
 Study 
  31.   23/f      Nil      Nil     Nil   Nil   Nil YES   Nil  Normal 
 Study 
 100 98  102 Normal 
 Study 
  32.  26/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98 90    109 Normal 
 Study 
  33.  32/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  89 90   99  Normal  
  Study  
  34.  33/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
    92 100      92 Normal 
 Study 
  35.  27/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  89   99     90 Normal 
 Study 
   S.    
  NO 
AGE 
/ SEX 
RECU
RRENT 
   RTI 
WHE
EZE 
B.AST
HMA 
COPD    TB  PREGN
ANCY 
SIGNS     X‐RAY FEV1 FVC FEV1/
FVC 
INFERENC
E  
  36.  27/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98 97  101 Normal 
 Study 
  37.  40/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
 105 98  107  Normal 
 Study 
  38.  15/m     YES    YES     YES   Nil   Nil wheez
e 
Normal 
 Study 
  90 106   84 Normal 
  Study 
  39.  31/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  84  76   118  Normal  
  Study  
  40.  29/m      YES    YES     YES   Nil Nil  wheez
e 
Normal 
 Study 
  84 98   85  Normal  
study 
  41.   31/f      Nil      Nil     YES   Nil Nil  wheez
e 
Normal 
 Study 
  92 105  88 Normal 
 Study 
  42.  34/m      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98  97 101 Normal 
 Study 
  43.   40/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  100 98  102 Normal 
 Study 
  44.    50/f      Nil      Nil     Nil   Nil   Nil   Nil  Normal 
 Study 
  98 90    109 Normal 
 Study 
  45    20/f      YES    YES     YES   Nil Nil  wheez
e 
Normal 
 Study 
  76 100  76 Obstructiv
e pattern 
  46.  21/m      YES    YES     YES NIL  Nil  wheez
e 
Normal 
 Study 
  78  98   79 Obstructiv
e pattern 
  47.  53/m      Nil      Nil     Nil YES   Nil   Nil  Emphyse
matous  
 53 92 57.6 Obstructiv
e pattern 
   S.    
  NO 
AGE 
/ SEX 
RECU
RRENT 
      RTI 
WHE
EZE 
B.AST
HMA 
COPD    TB  PREGN
ANCY 
SIGNS     X‐RAY FEV1 FVC FEV1/
FVC 
INFERENC
E  
  48.  53/m      YES     YES     Nil YES   Nil   Nil  Emphyse
matous 
lung 
  60 88 68.18 Obstructiv
e pattern 
  49.  36/m      YES    YES     Nil YES
 
  Nil   Nil  Emphyse
matous 
lung 
 55 88 62.5 Obstructiv
e pattern 
  50.  49/m      Nil      Nil     Nil YES   Nil   Nil  Emphyse
matous 
lung 
 62 80 77.5 Obstructiv
e pattern 
   
